Related references
Note: Only part of the references are listed.Population pharmacokinetics of mycophenolic acid in paediatric patients
Yan Rong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Mycophenolate mofetil, azathioprine and tacrolimus: mechanisms in rheumatology
Jasper C. A. Broen et al.
NATURE REVIEWS RHEUMATOLOGY (2020)
Effect of Protein Binding on Exposure of Unbound and Total Mycophenolic Acid: A Population Pharmacokinetic Analysis in Chinese Adult Kidney Transplant Recipients
Changcheng Sheng et al.
FRONTIERS IN PHARMACOLOGY (2020)
Population pharmacokinetics of mycophenolic acid in adult kidney transplant patients under prednisone and tacrolimus regimen
Juan Eduardo Resendiz-Galvan et al.
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES (2020)
Effect of the proton-pump Inhibitor pantoprazole on MycoPhenolic ACid exposure in kidney and liver transplant recipienTs (IMPACT study): a randomized trial
Andrew Sunderland et al.
NEPHROLOGY DIALYSIS TRANSPLANTATION (2020)
Population Pharmacokinetics of Mycophenolic Acid Co-Administered with Tacrolimus in Corticosteroid-Free Adult Kidney Transplant Patients
Yan Rong et al.
CLINICAL PHARMACOKINETICS (2019)
Population Pharmacokinetics of Mycophenolic Acid: An Update
Tony K. L. Kiang et al.
CLINICAL PHARMACOKINETICS (2018)
Therapeutic drug monitoring of mycophenolate in adult solid organ transplant patients: an update
Tony K. L. Kiang et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study
Olesja Rissling et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Variability of mycophenolic acid elimination in the renal transplant recipients - population pharmacokinetic approach
Radmila M. Velickovic-Radovanovic et al.
RENAL FAILURE (2015)
Pharmacokinetic modeling of enterohepatic circulation of mycophenolic acid in renal transplant recipients
Helena Colom et al.
KIDNEY INTERNATIONAL (2014)
Clinical Pharmacokinetics and Pharmacodynamics of Mycophenolate in Patients with Autoimmune Disease
Azrin N. Abd Rahman et al.
CLINICAL PHARMACOKINETICS (2013)
Development and Validation of Limited Sampling Strategies for the Estimation of Mycophenolic Acid Area Under the Curve in Adult Kidney and Liver Transplant Recipients Receiving Concomitant Enteric-Coated Mycophenolate Sodium and Tacrolimus
Tomasz Pawinski et al.
THERAPEUTIC DRUG MONITORING (2013)
Bayesian Estimation of Mycophenolate Mofetil in Lung Transplantation, Using a Population Pharmacokinetic Model Developed in Kidney and Lung Transplant Recipients
Brenda C. M. de Winter et al.
CLINICAL PHARMACOKINETICS (2012)
Nonlinear Relationship between Mycophenolate Mofetil Dose and Mycophenolic Acid Exposure: Implications for Therapeutic Drug Monitoring
Brenda C. M. de Winter et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
The Evolution of Population Pharmacokinetic Models to Describe the Enterohepatic Recycling of Mycophenolic Acid in Solid Organ Transplantation and Autoimmune Disease
Catherine M. T. Sherwin et al.
CLINICAL PHARMACOKINETICS (2011)
Mycophenolate, clinical pharmacokinetics, formulations, and methods for assessing drug exposure
Susan E. Tett et al.
TRANSPLANTATION REVIEWS (2011)
Differences in Clearance of Mycophenolic Acid Among Renal Transplant Recipients, Hematopoietic Stem Cell Transplant Recipients, and Patients With Autoimmune Disease
Brenda C. M. de Winter et al.
THERAPEUTIC DRUG MONITORING (2010)
Population Pharmacokinetic Analysis of Mycophenolic Acid Coadministered With Either Tasocitinib (CP-690,550) or Tacrolimus in Adult Renal Allograft Recipients
Manisha Lamba et al.
THERAPEUTIC DRUG MONITORING (2010)
Mechanism-Based Enterohepatic Circulation Model of Mycophenolic Acid and Its Glucuronide Metabolite: Assessment of Impact of Cyclosporine Dose in Asian Renal Transplant Patients
Wai-Ping Yau et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation
Y. Le Meur et al.
AMERICAN JOURNAL OF TRANSPLANTATION (2007)
Time-dependent clearance of mycophenolic acid in renal transplant recipients
Reinier M. van Hest et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2007)
Therapeutic monitoring of mycophenolate mofetil
Hyunyoung Jeong et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2007)
Therapeutic drug monitoring of mycophenolate mofetil in transplantation
T van Gelder et al.
THERAPEUTIC DRUG MONITORING (2006)
Characterizing the role of enterohepatic recycling in the interactions between mycophenolate mofetil and calcineurin inhibitors in renal transplant patients by pharmacokinetic modelling
S Cremers et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Abbreviated mycophenolic acid AUC from C0, C1, C2, and C4 is preferable in children after renal transplantation on mycophenolate mofetil and tacrolimus therapy
G Filler
TRANSPLANT INTERNATIONAL (2004)
Free mycophenolic acid should be monitored in renal transplant recipients with hypoalbuminemia
BA Atcheson et al.
THERAPEUTIC DRUG MONITORING (2004)
Population pharmacokinetics and Bayesian estimation of mycophenolic acid concentrations in stable renal transplant patients
C Le Guellec et al.
CLINICAL PHARMACOKINETICS (2004)
Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation
D Cattaneo et al.
KIDNEY INTERNATIONAL (2002)
Share Paper
